Tradename | Company | Number | Date | Products |
---|---|---|---|---|
GEMCITABINE HYDROCHLORIDE | Accord Healthcare | N-209604 RX | 2017-08-03 | 4 products, RLD, RS |
GEMCITABINE HYDROCHLORIDE | Hospira | N-200795 RX | 2011-08-04 | 3 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
gemcitabine | ANDA | 2025-02-03 |
gemcitabine gemcitabine | ANDA | 2019-09-12 |
gemcitabine hydrochloride | ANDA | 2025-01-09 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Gemcitabine Hydrochloride, Infugem, Sun Pharm | |||
9241948 | 2033-07-01 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 362 | 609 | 130 | 5 | 85 | 1025 |
Non-small-cell lung carcinoma | D002289 | — | — | 77 | 237 | 104 | 12 | 20 | 413 |
Lung neoplasms | D008175 | — | C34.90 | 64 | 227 | 84 | 9 | 18 | 370 |
Carcinoma | D002277 | — | C80.0 | 66 | 209 | 98 | 2 | 22 | 363 |
Adenocarcinoma | D000230 | — | — | 120 | 204 | 35 | 2 | 19 | 323 |
Neoplasms | D009369 | — | C80 | 242 | 110 | 20 | 2 | 8 | 321 |
Lymphoma | D008223 | — | C85.9 | 75 | 149 | 39 | 7 | 9 | 242 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 45 | 140 | 68 | 1 | 10 | 239 |
Urinary bladder neoplasms | D001749 | — | C67 | 44 | 135 | 40 | 2 | 18 | 212 |
Cholangiocarcinoma | D018281 | — | C22.1 | 42 | 124 | 28 | 1 | 15 | 189 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sarcoma | D012509 | — | — | 34 | 52 | 7 | — | 3 | 81 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 23 | 46 | 14 | — | 1 | 72 |
Gallbladder neoplasms | D005706 | EFO_0004606 | C23 | 17 | 43 | 16 | — | 5 | 71 |
B-cell lymphoma | D016393 | — | — | 30 | 44 | 14 | — | 1 | 70 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 27 | 35 | 9 | — | 1 | 62 |
Fallopian tube neoplasms | D005185 | — | — | 19 | 29 | 14 | — | — | 56 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 13 | 28 | 10 | — | 5 | 49 |
Kidney neoplasms | D007680 | EFO_0003865 | C64 | 10 | 32 | 2 | — | 1 | 42 |
Ureteral neoplasms | D014516 | EFO_0003844 | C66 | 11 | 27 | 4 | — | 1 | 38 |
Bile duct neoplasms | D001650 | — | — | 11 | 21 | 7 | — | 1 | 36 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 31 | 32 | — | — | 5 | 56 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 14 | 7 | — | — | 4 | 22 |
Esophageal neoplasms | D004938 | — | C15 | 9 | 5 | — | — | 2 | 15 |
Leukemia | D007938 | — | C95 | 6 | 8 | — | — | 1 | 14 |
Melanoma | D008545 | — | — | 9 | 6 | — | — | 2 | 14 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | 8 | 10 | — | — | — | 14 |
Multiple myeloma | D009101 | — | C90.0 | 5 | 10 | — | — | — | 12 |
Ewing sarcoma | D012512 | EFO_0000173 | — | 1 | 9 | — | — | — | 9 |
Plasma cell neoplasms | D054219 | — | — | 1 | 8 | — | — | — | 8 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 5 | 4 | — | — | — | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pseudomyxoma peritonei | D011553 | EFO_0007456 | — | 1 | — | — | — | 1 | 2 |
Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | 1 | 2 |
Diffuse intrinsic pontine glioma | D000080443 | — | — | 2 | — | — | — | — | 2 |
Connective and soft tissue neoplasms | D018204 | — | — | 1 | — | — | — | — | 1 |
Pharyngeal neoplasms | D010610 | — | C14.0 | 1 | — | — | — | — | 1 |
Rhabdoid tumor | D018335 | — | — | 1 | — | — | — | — | 1 |
Meningioma | D008579 | EFO_0003098 | D32.9 | 1 | — | — | — | — | 1 |
Ependymoma | D004806 | — | — | 1 | — | — | — | — | 1 |
Astrocytoma | D001254 | EFO_0000271 | — | 1 | — | — | — | — | 1 |
Choroid plexus neoplasms | D016545 | EFO_0007206 | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prognosis | D011379 | — | — | — | — | — | — | 2 | 2 |
Acute disease | D000208 | — | — | — | — | — | — | 1 | 1 |
Multiple primary neoplasms | D009378 | — | — | — | — | — | — | 1 | 1 |
Brain death | D001926 | — | G93.82 | — | — | — | — | 1 | 1 |
Ascites | D001201 | — | R18 | — | — | — | — | 1 | 1 |
Appendiceal neoplasms | D001063 | EFO_0003880 | C18.1 | — | — | — | — | 1 | 1 |
Pleural neoplasms | D010997 | — | — | — | — | — | — | 1 | 1 |
Maintenance chemotherapy | D060046 | — | — | — | — | — | — | 1 | 1 |
Liver transplantation | D016031 | EFO_0010682 | — | — | — | — | — | 1 | 1 |
Hypoxia | D000860 | — | R09.02 | — | — | — | — | 1 | 1 |
Drug common name | Gemcitabine |
INN | gemcitabine |
Description | Gemcitabine is a 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It has a role as a photosensitizing agent, a DNA synthesis inhibitor, a prodrug, an EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor, an environmental contaminant, a xenobiotic, a radiosensitizing agent, an antineoplastic agent, an antimetabolite, an antiviral drug and an immunosuppressive agent. It is an organofluorine compound and a pyrimidine 2'-deoxyribonucleoside. |
Classification | Small molecule |
Drug class | nucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1 |
PDB | — |
CAS-ID | 95058-81-4 |
RxCUI | — |
ChEMBL ID | CHEMBL888 |
ChEBI ID | 175901 |
PubChem CID | 60750 |
DrugBank | DB00441 |
UNII ID | B76N6SBZ8R (ChemIDplus, GSRS) |